Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker OCUL
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | Namrata Saroj Chief Business Officer | OCUL Ocular Therapeutix, Inc. | Sale | 35,370 | $6.55 | $231.7K Sale | Form 4 ↗ |
| Aug 31, 2026 | Donald Notman Chief Operating Officer | OCUL Ocular Therapeutix, Inc. | Sale | 1,099 | $10.24 | $11.3K Sale | Form 4 ↗ |
| Aug 24, 2026 | Peter Kaiser Chief Development Officer | OCUL Ocular Therapeutix, Inc. | Sale | 3,035 | $10.77 | $32.7K Sale | Form 4 ↗ |
| Aug 24, 2026 | Sanjay Nayak Chief Strategy Officer | OCUL Ocular Therapeutix, Inc. | Sale | 1,897 | $10.78 | $20.4K Sale | Form 4 ↗ |
| Aug 24, 2026 | Jeffrey S. Heier Chief Scientific Officer | OCUL Ocular Therapeutix, Inc. | Sale | 3,296 | $10.78 | $35.5K Sale | Form 4 ↗ |
| Aug 24, 2026 | Pravin Dugel See Remarks, Director | OCUL Ocular Therapeutix, Inc. | Sale | 21,649 | $10.77 | $233.2K Sale | Form 4 ↗ |
| Jun 3, 2026 | Nadia Waheed Chief Medical Officer | OCUL Ocular Therapeutix, Inc. | Sale | 14,828 | $8.27 | $122.6K Sale | Form 4 ↗ |
| May 26, 2026 | Pravin Dugel See Remarks, Director | OCUL Ocular Therapeutix, Inc. | Sale | 21,156 | $8.20 | $173.5K Sale | Form 4 ↗ |
| May 26, 2026 | Peter Kaiser Chief Development Officer | OCUL Ocular Therapeutix, Inc. | Sale | 2,967 | $8.20 | $24.3K Sale | Form 4 ↗ |
| May 26, 2026 | Jeffrey S. Heier Chief Scientific Officer | OCUL Ocular Therapeutix, Inc. | Sale | 3,018 | $8.20 | $24.7K Sale | Form 4 ↗ |
| May 26, 2026 | Sanjay Nayak Chief Strategy Officer | OCUL Ocular Therapeutix, Inc. | Sale | 1,858 | $8.20 | $15.2K Sale | Form 4 ↗ |
| Feb 23, 2026 | Pravin Dugel See Remarks, Director | OCUL Ocular Therapeutix, Inc. | Sale | 20,056 | $8.28 | $166.1K Sale | Form 4 ↗ |
| Feb 23, 2026 | Peter Kaiser Chief Development Officer | OCUL Ocular Therapeutix, Inc. | Sale | 2,810 | $8.28 | $23.3K Sale | Form 4 ↗ |
| Feb 23, 2026 | Jeffrey S. Heier Chief Scientific Officer | OCUL Ocular Therapeutix, Inc. | Sale | 3,057 | $8.28 | $25.3K Sale | Form 4 ↗ |
| Feb 23, 2026 | Sanjay Nayak Chief Strategy Officer | OCUL Ocular Therapeutix, Inc. | Sale | 1,759 | $8.28 | $14.6K Sale | Form 4 ↗ |
| Feb 20, 2026 | Nadia Waheed Chief Medical Officer | OCUL Ocular Therapeutix, Inc. | Sale | 3,510 | $7.74 | $27.2K Sale | Form 4 ↗ |
| Feb 20, 2026 | Richard L. Lindstrom MD Director | OCUL Ocular Therapeutix, Inc. | Buy | 60,229 | $7.66 | $461.4K Buy | Form 4 ↗ |
| Feb 12, 2026 | Donald Notman Chief Operating Officer | OCUL Ocular Therapeutix, Inc. | Sale | 11,446 | $9.04 | $103.5K Sale | Form 4 ↗ |
| Feb 12, 2026 | Sanjay Nayak Chief Strategy Officer | OCUL Ocular Therapeutix, Inc. | Sale | 10,348 | $9.04 | $93.5K Sale | Form 4 ↗ |
| Feb 12, 2026 | Pravin Dugel See Remarks, Director | OCUL Ocular Therapeutix, Inc. | Sale | 124,882 | $9.04 | $1.1M Sale | Form 4 ↗ |
| Feb 12, 2026 | Nadia Waheed Chief Medical Officer | OCUL Ocular Therapeutix, Inc. | Sale | 7,863 | $9.04 | $71.1K Sale | Form 4 ↗ |
| Feb 4, 2026 | Donald Notman Chief Operating Officer | OCUL Ocular Therapeutix, Inc. | Sale | 6,035 | $8.54 | $51.5K Sale | Form 4 ↗ |
| Feb 2, 2026 | Donald Notman Chief Operating Officer | OCUL Ocular Therapeutix, Inc. | Sale | 5,455 | $9.14 | $49.9K Sale | Form 4 ↗ |
| Nov 24, 2025 | Sanjay Nayak Chief Strategy Officer | OCUL Ocular Therapeutix, Inc. | Sale | 1,878 | $12.04 | $22.6K Sale | Form 4 ↗ |
| Nov 24, 2025 | Pravin Dugel See Remarks, Director | OCUL Ocular Therapeutix, Inc. | Sale | 19,530 | $12.04 | $235.1K Sale | Form 4 ↗ |
| Nov 24, 2025 | Peter Kaiser Chief Development Officer | OCUL Ocular Therapeutix, Inc. | Sale | 3,007 | $12.02 | $36.1K Sale | Form 4 ↗ |
| Nov 24, 2025 | Jeffrey S. Heier Chief Scientific Officer | OCUL Ocular Therapeutix, Inc. | Sale | 3,469 | $12.04 | $41.8K Sale | Form 4 ↗ |
| Nov 5, 2025 | Namrata Saroj Chief Business Officer | OCUL Ocular Therapeutix, Inc. | Sale | 25,865 | $10.74 | $277.8K Sale | Form 4 ↗ |
| Oct 8, 2025 | Todd Anderman Chief Legal Officer | OCUL Ocular Therapeutix, Inc. | Sale | 11,132 | $12.34 | $137.4K Sale | Form 4 ↗ |
| Oct 2, 2025 | Peter Kaiser Chief Development Officer | OCUL Ocular Therapeutix, Inc. | Sale | 9,653 | $11.03 | $106.5K Sale | Form 4 ↗ |
| Oct 2, 2025 | Jeffrey S. Heier Chief Scientific Officer | OCUL Ocular Therapeutix, Inc. | Sale | 10,502 | $11.04 | $115.9K Sale | Form 4 ↗ |
| Sep 2, 2025 | Donald Notman See Remarks | OCUL Ocular Therapeutix, Inc. | Sale | 1,066 | $12.43 | $13.3K Sale | Form 4 ↗ |
| Aug 25, 2025 | Peter Kaiser Chief Development Officer | OCUL Ocular Therapeutix, Inc. | Sale | 3,011 | $12.04 | $36.3K Sale | Form 4 ↗ |
| Aug 25, 2025 | Sanjay Nayak Chief Strategy Officer | OCUL Ocular Therapeutix, Inc. | Sale | 1,885 | $12.04 | $22.7K Sale | Form 4 ↗ |
| Aug 25, 2025 | Jeffrey S. Heier Chief Scientific Officer | OCUL Ocular Therapeutix, Inc. | Sale | 3,063 | $12.04 | $36.9K Sale | Form 4 ↗ |
| Aug 25, 2025 | Pravin Dugel See Remarks, Director | OCUL Ocular Therapeutix, Inc. | Sale | 21,494 | $12.04 | $258.8K Sale | Form 4 ↗ |
| Jun 2, 2025 | Nadia Waheed Chief Medical Officer | OCUL Ocular Therapeutix, Inc. | Sale | 13,861 | $8.05 | $111.6K Sale | Form 4 ↗ |
| May 23, 2025 | Sanjay Nayak Chief Strategy Officer | OCUL Ocular Therapeutix, Inc. | Sale | 1,862 | $7.17 | $13.4K Sale | Form 4 ↗ |
| May 23, 2025 | Peter Kaiser Chief Development Officer | OCUL Ocular Therapeutix, Inc. | Sale | 2,974 | $7.17 | $21.3K Sale | Form 4 ↗ |
| May 23, 2025 | Jeffrey S. Heier Chief Scientific Officer | OCUL Ocular Therapeutix, Inc. | Sale | 3,024 | $7.18 | $21.7K Sale | Form 4 ↗ |
| May 23, 2025 | Pravin Dugel See Remarks, Director | OCUL Ocular Therapeutix, Inc. | Sale | 21,219 | $7.18 | $152.4K Sale | Form 4 ↗ |
| May 8, 2025 | Richard L. Lindstrom MD Director | OCUL Ocular Therapeutix, Inc. | Buy | 10,000 | $6.96 | $69.6K Buy | Form 4 ↗ |
| Feb 24, 2025 | Pravin Dugel See Remarks, Director | OCUL Ocular Therapeutix, Inc. | Sale | 21,475 | $6.87 | $147.5K Sale | Form 4 ↗ |
| Feb 24, 2025 | Jeffrey S. Heier Chief Scientific Officer | OCUL Ocular Therapeutix, Inc. | Sale | 3,061 | $6.87 | $21.0K Sale | Form 4 ↗ |
| Feb 24, 2025 | Peter Kaiser Chief Development Officer | OCUL Ocular Therapeutix, Inc. | Sale | 3,009 | $6.87 | $20.7K Sale | Form 4 ↗ |
| Feb 24, 2025 | Sanjay Nayak Chief Strategy Officer | OCUL Ocular Therapeutix, Inc. | Sale | 1,895 | $6.84 | $13.0K Sale | Form 4 ↗ |
| Feb 4, 2025 | Donald Notman See Remarks | OCUL Ocular Therapeutix, Inc. | Sale | 11,119 | $7.81 | $86.8K Sale | Form 4 ↗ |
| Jan 31, 2025 | Donald Notman See Remarks | OCUL Ocular Therapeutix, Inc. | Sale | 6,301 | $7.84 | $49.4K Sale | Form 4 ↗ |
| Nov 25, 2024 | Jeffrey S. Heier Chief Scientific Officer | OCUL Ocular Therapeutix, Inc. | Sale | 2,948 | $9.01 | $26.6K Sale | Form 4 ↗ |
| Nov 25, 2024 | Peter Kaiser Chief Development Officer | OCUL Ocular Therapeutix, Inc. | Sale | 2,897 | $9.01 | $26.1K Sale | Form 4 ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:03 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances